SEC Form 4 · accession 0000899243-16-011133
Coherus Oncology, Inc. · CHRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alan C. Herman
Officer — Chief Scientific Officer
Period of report
Jan 4, 2016
Accepted (ET)
Jan 6, 2016 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001512762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF2 | Jan 4, 2016 | S | 3,950 | $21.4038 | D | 223,915 | D | |
| Common Stock, $0.0001 par valueF3 | Jan 4, 2016 | S | 300 | $22.3567 | D | 223,615 | D | |
| Common Stock, $0.0001 par valueF4 | holding | — | — | — | 300,164 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
- F2The transaction was executed in multiple trades in prices ranging from $21.06 to $21.85, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- F3The transaction was executed in multiple trades in prices ranging from $22.30 to $22.44, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- F4These shares are held by the Herman Trust, dated March 16, 2001, of which Reporting Person is a co trustee.